Physician profile
Rizwana Syed
NPI 1447506597
$1,142.53
in general payments reported to CMS, 2019-2025
14 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $175 · 2021: $224 · 2022: $163 · 2023: $150 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $319.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $219.79 | 2019-2020 | |
| Genzyme Corporation | $150.00 | 2023 | |
| Pfizer INC. | $138.94 | 2019-2025 | |
| Incyte Corporation | $126.73 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $124.52 | 2021 | |
| Kite Pharma, INC. | $97.47 | 2022 | |
| Janssen Pharmaceuticals, INC | $70.53 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $53.96 | 2019 | |
| Janssen Biotech, INC. | $48.21 | 2022-2025 | Darzalex, Talvey |
| Astrazeneca Pharmaceuticals LP | $37.13 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $23.27 | 2022 | |
| Sanofi Pasteur INC. | $21.60 | 2019 | |
| Lilly USA, LLC | $18.71 | 2025 | Verzenio, Jaypirca |
| Merck Sharp & Dohme LLC | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rizwana Syed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.